In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

ACVC Biomarker Talks

A project by the ACVC Biomarkers Study Group

Association for Acute CardioVascular Care
Acute Cardiac Care

A series of concise and interactive, online events covering the full spectrum of biomarkers.

Each talk will be followed by an editorial article published in the EHJ-ACVC.



Discover the ACVC Biomarker Talks

Smart student learning using internet and headphonesThis series was designed by course directors Christian Müller and Nicholas Mills, chair and co-chair of the ACVC study group on biomarkers.

 

In a nutshell

  • live and interactive online events covering each topic in the biomarker field;
  • Each talk will be moderated by Christian Mueller and Nicholas Mills, and presented by one expert;
  • Each talk will last for 30 minutes and will include a 15-20 min state-of-the-art presentation and 10-15 min discussions with the audience;
  • The on-demand video will be available 24 hours after the live event.

 

  Register for the entire series

 

 Upcoming Talks

How to implement novel diagnostic algorithms in the emergency room (19 January 2022)

Speaker: Louise Cullen

Learning objectives

After watching this webinar, participants will be able to:

  • understand that translating research protocols into effective clinical care is not straightforward;
  • appreciate that teamwork, planning, and education are essential steps in the implementation of diagnostic algorithms;
  • know that when implementation is effective the benefits for patients and healthcare systems can be substantial; and
  • identify opportunities to improve performance of current diagnostic algorithms.

Discover the talk

Future application of POC in the emergency room (23 February 2022)

Speaker: Rick Body

Learning objectives

After watching this webinar, participants will be able to:

  • understand the major sensitivity deficit of most currently used POC cTnT/I assays and the clinical consequences – second blood sampling at 6h;
  • identify the possibility for reduction in turn-around time when using POC versus central lab;
  • know the assay-specific performance data (and their limitations) for the first commercially available POC hs-cTnI assays, including their assay-specific ESC hs-cTnI 0/1h-algorithms; and
  • appreciate the opportunity and emerging data for other POC CV biomarkers.

Discover the talk

Blood and imaging biomarkers in type 2 myocardial infarction (30 March 2022)

Speaker: Andrew Chapman

Learning objectives

After watching this webinar, participants will be able to:

  • understand the diagnostic criteria for type 2 myocardial infarction;
  • know that the mechanism of myocardial oxygen supply-demand imbalance is important and influences treatment and outcomes;
  • appreciate that cardiac imaging can play an important role in evaluating type 2 myocardial infarction; and
  • identify the potential role for blood biomarkers to support the diagnosis and assessment of patients with type 2 myocardial infarction.

Discover the talk

How to deal with unexpected cardiac troponin results (April 2022)

Speaker: Johannes Mair

Learning objectives

After watching this webinar, participants will be able to:

  • understand that the majority of unexpected cTn results are true due to the higher sensitivity of cTn for cardiomyocyte injury vs. cardiac imaging;
  • know the concept of verifying unexpected cTn results: 1) measure from a new sample 2) measure also the other cTn (e.g. cTnI if cTnT was measured before) 3) proceed with cardiac imaging;
  • know the pathophysiological causes of possible ‘false cTn’ elevations: 1) sample from other patient 2) chronic skeletal muscle disease such as myopathy and myositis for cTnT 3) hetreophilic antibodies for cTnI; and
  • appreciate the opportunity and emerging data for other POC CV biomarkers.

 

Use of BNP and NT-proBNP in the emergency room (May 2022)

Speaker: Lori Daniels

Learning objectives

After watching this webinar, participants will be able to:

  • understand the unmet need without BNP/NT-proBNP – symptoms and signs of HF have insufficient sensitivity and specificity. Therefore, relevant uncertainty regarding the presence of HF remains without BNP/NT-proBNP;
  • know the basic concept of NP pathophysiology – BNP/NT-proBNP are quantitative markers of hemodynamic cardiac stress and, therefore, HF. They quantify the presence and extent of LV systolic dysfunction, LV diastolic dysfunction, valvular dysfunction, and RV dysfunction;
  • appreciate the similarities and small differences between BNP and NT-proBNP;
  • understand the strong scientific bases for the use of BNP/NT-proBNP in the ER – very high and incremental diagnostic accuracy in diagnostic studies, reduced time to decision, and time to discharge in RCTs;
  • know the specific rule-out and rule-in cutoffs to be applied in the ER; and
  • understand obesity as the most important confounder and the concept on how to adjust for obesity.

 

Origin and future of cardiac troponin I (June 2022)

Speaker: Fred Apple

Learning objectives

After watching this webinar, participants will be able to:

  • gain insight into the development of an assay for cardiac troponin I;
  • appreciate the difference between high-sensitivity and contemporary sensitive assays;
  • understand the similarities and differences between cardiac troponin I and T in the lab and in practice; and
  • know how the role for cardiac troponin I testing will evolve in the future.

 

Screening the general population – a role for cardiac biomarkers? (July 2022)

Speaker: Stefan Blankenberg

Learning objectives

After watching this webinar, participants will be able to:

  • understand the fundamental differences between screening and diagnosis;
  • know the basic concept of cTn and NP pathophysiology cTn as quantitative markers of cardiomyocyte injury, while BNP/NT-proBNP are quantitative markers of hemodynamic cardiac stress and, therefore, HF;
  • appreciate the fact that many cardiac disorders develop during decades in a clinically silent period, with cardiac biomarkers as sensitive tools for relevant pathophysiological cardiac changes;
  • understand the possible therapeutic consequences of screening; and
  • know available data and their limitations.

More ACVC Biomarker Talks will be announced later.

 

 Past Talks

Date Episodes Title Presented by
24 November 2021 Episode 4   Biomarkers in atrial fibrillation Ziad Hijazi
27 October 2021 Episode 3   A new diagnostic marker on the horizon - cMyC Michael Marber
23 June 2021 Episode 2   Rapid diagnostic algorithms for NSTEMI Maria Rubini Gimenez
19 May 2021 Episode 1   CV biomarkers in COVID-19 Torbjørn Omland

 

Discover the ACVC Biomarker Talks

The ACVC Study Group on Biomarkers

Background

The ACVC study group on biomarkers was established by Kristian Thygesen (DK) in 2005 with the intention of creating a support group for the Global Task Force for the Definition of Myocardial Infarction (later called Universal Definition of Myocardial Infarction - UDMI).

In addition to supporting the UDMI, this group became successful and independent and now focuses on the proper clinical application of cardiac biomarkers including troponins, natriuretic peptides, and inflammatory and thrombotic markers in acute cardiac care.

Objectives

  • disseminating  knowledge about the proper clinical application of cardiac biomarkers in acute cardiovascular care; 
  • advising on the appropriate application of biomarkers in cardiovascular research;
  • creating recommendations/guidelines for implementation of cardiac biomarkers in acute cardiac care; and
  • being a counselling source for authorities regarding the appropriate clinical use of cardiac biomarkers.